EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Sandip P Patel iD, Megan Othus, Young Kwang Chae iD, Tridu Huynh, Benjamin Tan, Timothy Kuzel, Christine McLeod, Gabby Lopez, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009074 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Sandip P Patel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California San Diego, La Jolla, California, USA spatel@ucsd.edu chaelabmeeting@gmail.com rkurzrock@mcw.edu. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, CTLA-4 Antigen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, SWOG Operations Office, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors. Design/setting A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.

Participants

21 eligible patients were registered. Median age was 53 years (range 26–69); 16 (76%) were women.

Interventions

Ipilimumab 1 mg/kg intravenously every 6 weeks with nivolumab 240 mg intravenously every 2 weeks was administered until disease progression, symptomatic deterioration, treatment delay for any reason >56 days, unacceptable or immune-related toxicity with inability to decrease prednisone to 6 months), progression-free survival (PFS), overall survival (OS), and toxicity. Immune-related outcomes included immune ORR (iORR), immune CBR (iCBR), and immune PFS (iPFS). A two-stage design was used assuming: null=5% alternative=30%, n=6 in the first stage, 16 max, one-sided alpha=13%.

Results

The median number of prior therapy lines was 2 (range: 1–9). 3 of 21 patients attained confirmed partial response (PR) (ORR=14%). In addition, one patient had an unconfirmed PR; one, stable disease (SD)>6 months; one, immune-related RECIST (iRECIST) PR (iPR); and one patient attained iSD>6 months: clinical benefit rate (response or SD>6 months)=5/21 (24%), iORR=4/21 (19%), iCBR=7/21 (33%). The 6-month PFS was 24%; 6-month iPFS, 33%. The PFS for patients (N=7) with iRECIST clinical benefit were 57, 52, 18, 15, 13, 7, and 7 months. The 6-month OS was 76%; the median OS, was 15.8 months. The most common toxicities were fatigue (62%) and rash (38%), and the most common grade 3/4 immune-related adverse events were hepatic dysfunction (9.5%) and adrenal insufficiency (9.5%). Treatment-related adverse events leading to discontinuation of therapy in four patients (21%). There were no grade 5 adverse events.

Conclusions

Ipilimumab plus nivolumab is active in refractory metastatic adrenocortical cancer meeting the primary endpoint of the study, with a 19% iORR and 33% iCBR (includes SD/iSD>6 months) and with the longest PFS/iPFS of 52 and 57 months. Trial registration number NCT02834013 (registered 15 July, 2016; https://clinicaltrials.gov/ct2/show/NCT02834013 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaCTLA-4 AntigenHumansFemaleMiddle AgedMaleAdultAgedImmune Checkpoint InhibitorsIpilimumabProspective StudiesProgrammed Cell Death 1 ReceptorAdrenal Cortex NeoplasmsNivolumabAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Combination therapyImmune Checkpoint InhibitorImmune modulatoryImmunotherapyNeuroendocrine and Adrenal Tumor

Substanzen

CTLA-4 AntigenImmune Checkpoint InhibitorsIpilimumabCTLA4 protein, humanProgrammed Cell Death 1 ReceptorNivolumabPDCD1 protein, human

Autor:innen und Institutionen

  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA spatel@ucsd.edu chaelabmeeting@gmail.com rkurzrock@mcw.edu.
  • Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Northwestern University, Chicago, Illinois, USA spatel@ucsd.edu chaelabmeeting@gmail.com rkurzrock@mcw.edu.
  • UC San Diego Moores Cancer Center, La Jolla, California, USA.
  • Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
  • Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

ORCID-Profile: Sandip P Patel, Young Kwang Chae

Förderung

  • NCI NIH HHS
  • SWOG Operations Office
  • National Institutes of Health, National Cancer Institute
  • Bristol-Myers Squibb Company
  • National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program
  • ICAN-International Cancer Advocacy Network
  • National Institutes of Health
  • Ms. Marcia Horn, JD

Zitieren

APA

Patel, S. P., Othus, M., Chae, Y. K., Huynh, T., Tan, B., Kuzel, T., McLeod, C., Lopez, G., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C., & Kurzrock, R. (2024). Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009074

Vancouver

Patel SP, Othus M, Chae YK, Huynh T, Tan B, Kuzel T, et al. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009074

BibTeX
@article{Patel2024,
  author = {Patel, Sandip P and Othus, Megan and Chae, Young Kwang and Huynh, Tridu and Tan, Benjamin and Kuzel, Timothy and McLeod, Christine and Lopez, Gabby and Chen, Helen X and Sharon, Elad and Streicher, Howard and Ryan, Christopher W and Blanke, Charles and Kurzrock, Razelle},
  title = {Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009074}
}
Kostenlos starten →